![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Treatment with Telaprevir/Peg-IFN/RBV After 14-day Telaprevir Exposure in Phase I Studies: Results from the Phase IIIB C219 Rollover Study
|
|
|
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
Christoph Sarrazin,1 Henk W Reesink,2 Stefan Zeuzem,1 Inge Dierynck,3 Don Luo,4 James Witek,4 Gaston Picchio,4 Sandra De Meyer3
1Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 2Academic Medical Center, Amsterdam, The Netherlands; 3Janssen Infectious Diseases, Beerse, Belgium; 4Janssen Research and Development LLC, NJ, USA
![EASL1.gif](../images/050713/050713-1/EASL1.gif)
![EASL2.gif](../images/050713/050713-1/EASL2.gif)
![EASL3.gif](../images/050713/050713-1/EASL3.gif)
![EASL4.gif](../images/050713/050713-1/EASL4.gif)
![EASL5.gif](../images/050713/050713-1/EASL5.gif)
![EASL6.gif](../images/050713/050713-1/EASL6.gif)
![EASL7.gif](../images/050713/050713-1/EASL7.gif)
![EASL8.gif](../images/050713/050713-1/EASL8.gif)
![EASL9.gif](../images/050713/050713-1/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|